Navigation Links
Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
Date:9/17/2009

the end of the trial to assess heart valve function over time. In contrast to the BLOOM trial, there were no echocardiographic exclusion criteria for entry into BLOSSOM and there was no oversight or interim data review monitoring by an independent safety monitoring board.

Phase 3 Program Overview

The lorcaserin Phase 3 program consists of three trials: BLOOM, BLOSSOM and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus). Enrollment in the lorcaserin Phase 3 program is complete with approximately 7,800 patients. Positive results from BLOOM were presented at the 69th Scientific Sessions of the American Diabetes Association in June 2009. BLOOM and BLOSSOM comprise the Phase 3 pivotal registration program and will be the basis for the lorcaserin NDA submission. BLOOM-DM, which is planned as a supplement to the NDA, is evaluating 10 mg of lorcaserin dosed once or twice daily versus placebo over a one-year treatment period in obese and overweight patients with type 2 diabetes at about 60 sites in the US.

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-primary efficacy endpoints are: the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Arena is also studying several key secondary endpoints, including changes in serum lipids, markers of inflammation and insulin resistance, and in the BLOOM-DM trial, other indicators of glycemic control.

About the FDA Draft Guidance

The FDA draft guidance document "Developing Products for Weight Management" dated February 2007 provides recommendations regarding the development of drugs for t
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Inc. (NYSE: CRY ), a leading medical device ... surgery, announced today that its Board of Directors has ... 2015 of $0.03 per share of common stock outstanding.  ... be paid on June 19, 2015 to all common ... ex-dividend date for the quarterly dividend is June 10, ...
(Date:5/21/2015)... -- The Pharmaceutical Care Management Association (PCMA) issued ... offsets included in the Energy & Commerce Committee,s ... 21st Century Cures initiative can only be advanced by ... Medicare – then its costs outweigh any potential ... "Leveraging payments to Part D plans to ...
(Date:5/21/2015)... 2015  Heidrick & Struggles (Nasdaq: HSII ), ... leadership consulting and culture shaping worldwide, ... practices announcing the addition of Tim Dietlin ... Dietlin has extensive life sciences and ... R&D, Medical and Commercial functions to increase productivity, drive ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Heidrick Increases Healthcare and Life Sciences Expertise 2
... 1, 2012  ProUroCare Medical Inc. (OCTBB: PUMD), provider ... has received clearance from the U.S. Food & ... imaging (PMI) system.  The approval paves the way ... visual documentations as an aid in detecting prostate ...
... 1, 2012 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... conferences in May 2012: Deutsche Bank 37th Annual Healthcare ... Bank of America Merrill Lynch 2012 Healthcare Conference Tuesday, May ... live webcast of each event will be available on the Investor ...
Cached Medicine Technology:ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System 2ProUroCare Medical Receives FDA Clearance for ProUroScan Elasticity Imaging System 3
(Date:5/23/2015)... AZ (PRWEB) May 23, 2015 Manufacturers are ... Seasonal Performance Factor (HSPF) of 8.2. Experts in the field ... ultimately benefit consumers. , The HSPF score is what miles ... the more efficient the unit. Although the minimum HSPF score ... water heaters with an HSPF score north of 12. Indeed, ...
(Date:5/23/2015)... 23, 2015 Add High-Quality prismatic refractions into ... Studios. , It's as simple as dragging and dropping footage ... tool for full effect. , Including over 80 stunning ... 5k sensors making this the ultimate bundle for adding prismatic ... in this package are movie files designed for Final Cut ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood company in ... reclaimed wood, introducing their latest reclaimed wood products at ... offerings, Vat 35, Reclaimed Teak , and Prairie ... largest design event. , “Designers, architects, builders, and homeowners ... see and feel the variety of wood surfaces in ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton Hershey ... Congress of Future Medical Leaders in Boston, Mass. The ... highest achieving high school students.” , “I’m excited to ... and learn better study habits,” said Omar. “The event ... can ask the surgeons questions.” , The goal is ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2
... are more effective at delivering protection against influenza virus ... detailed analysis of the early immune responses by the ... the skin is such fertile ground for vaccination with ... was published in the January/February issue of the online ...
... "report cards" to grade health care providers, greater attention to ... such efforts, according to a new RAND Corporation study. ... care providers can do much to improve the nation,s health ... author and researcher at RAND, a nonprofit research organization. "But ...
... PHILADELPHIA - Researchers from the Perelman School of Medicine ... Cancer Research a universal approach to personalized cancer therapy ... a system for making an adaptable, engineered T-cell to ... which abnormal proteins, called antigens, are expressed by individual ...
... -- Preteen and teenage girls whose diets are rich in ... particularly if they are involved in high-impact activities, according to ... followed over 6,700 girls, ranging in age from 9 to ... of seven years. The study, published in the March 5 ...
... and high-school students who bully their classmates are more likely ... marijuana, a new study found. Researchers found that bullies ... were more likely to use substances than were victims ... behavior may be related to another," said Kisha Radliff, lead ...
... -- Children with asthma have a higher risk for developing ... the herpes zoster virus, new research reveals. The authors ... with the herpes zoster virus every year. However, typically it,s ... of 60 or people with weakened immune systems. Researchers ...
Cached Medicine News:Health News:Microneedle vaccine patch boosts flu protection through robust skin cell immune response 2Health News:Report suggests ways to improve health-care provider 'report cards' 2Health News:New universal platform for cancer immunotherapy developed by Penn-led team 2Health News:New universal platform for cancer immunotherapy developed by Penn-led team 3Health News:Vitamin D May Cut Stress Fracture Risk in Girls 2Health News:School bullies more likely to be substance users, study finds 2Health News:School bullies more likely to be substance users, study finds 3Health News:Children With Asthma at Higher Risk for Shingles: Study 2
... The SYNCHRON CX4 Delta Specialty ... random access analyzer that can consolidate ... specialty testing, such as thyroid, HbA1c ... The CX4 Delta offers a level ...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: